Minerva Minerva

Minerva

BMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7241.1086 (Published 15 April 2000) Cite this as: BMJ 2000;320:1086

The BMJ is looking for a chairperson to recruit and lead a new editorial ethics committee. If you are interested in the ethical and moral dimensions of editorial policy, have experience in chairing a team, and can spare us a few hours every quarter (all expenses paid), we would like to hear from you. Contact Alison Tonks (atonks@bmj.com) or Richard Smith (gshockley@bmj.com) for further details. The deadline for applications is 21 April.

The levonorgestrel intrauterine system combines the action of an intrauterine device with the release of the hormone into the uterine cavity, thus providing contraception and (usually) reducing menstrual blood loss. A study of 17 914 women in Finland (British Journal of Obstetrics and Gynaecology 2000;107:335-9) found that the continuation rate at five years was 65%—a rate that compares well with other long acting methods of contraception.

According to the World Health Organization, in the next 25 years the numbers of people known to have diabetes will rise from 130 million to 300 million. Half of these will develop neuropathy, and a review in Annals of Medicine (2000;32:1-5) comments that current treatments are unsatisfactory. The best prospect seems to be prevention by treatment with angiotensin converting enzyme inhibitor drugs.

Dizziness is …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe